Word

EXPLORE44

Status

Pending

Status Code

688

Status Date

Tuesday, May 14, 2024

Serial Number

97597519

Mark Type

4

Filing Date

Monday, September 19, 2022

Published for Opposition

Tuesday, August 22, 2023

Trademark Owner History

Avidity Biosciences, Inc. - Owner At Publication

Classifications

5 Therapeutic pharmaceuticals in the nature of oligonucleotide-conjugate based therapies, oligonucleotide-antibody conjugate based therapies, and oligonucleotide-antibody fragment conjugate based therapies for the treatment of viral, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, neuromuscular, rare muscle diseases, cardiomyopathies, heart muscle diseases, muscular dystrophies, muscle atrophy, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and related diseases and disorders, none of the aforementioned offerings being in the nature of dietetic substances for medical use, foods for special medical purposes, or special nutritional food products for medical purposes.

42 Scientific research in the nature of conducting clinical trials for others in the fields of pharmaceuticals and biotechnology, namely, conducting clinical trials for the treatment of viral, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, neuromuscular, rare muscle diseases, cardiomyopathies, heart muscle diseases, muscular dystrophies, muscle atrophy, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and related diseases and disorders; providing medical and scientific research information in the fields of pharmaceuticals and biotechnology; medical and scientific research, namely, conducting clinical trials for others for oligonucleotide-based therapeutics, none of the aforementioned offerings being in the nature of dietetic substances for medical use, foods for special medical purposes, or special nutritional food products for medical purposes.

EXPLORE FORTY FOUR; EXPLORE FOUR FOUR

Trademark Events

Jul 10, 2023

Non-Final Action E-Mailed

Sep 22, 2022

New Application Entered

Oct 5, 2022

New Application Office Supplied Data Entered

Jun 28, 2023

Assigned To Examiner

Jul 10, 2023

Non-Final Action Written

Jul 10, 2023

Notification Of Non-Final Action E-Mailed

Jul 13, 2023

Teas Response To Office Action Received

Jul 13, 2023

Correspondence Received In Law Office

Jul 14, 2023

Teas/Email Correspondence Entered

Jul 17, 2023

Approved For Pub - Principal Register

Aug 2, 2023

Notification Of Notice Of Publication E-Mailed

Aug 22, 2023

Published For Opposition

Aug 22, 2023

Official Gazette Publication Confirmation E-Mailed

Sep 20, 2023

Extension Of Time To Oppose Received

Feb 23, 2024

Teas Post Publication Amendment Received

Feb 29, 2024

Extension Of Time To Oppose Process - Terminated

Apr 1, 2024

Assigned To Petition Staff

Apr 3, 2024

Changes/Corrections After Pub Approval Entered

May 14, 2024

Noa E-Mailed - Sou Required From Applicant

Jul 31, 2024

Teas Statement Of Use Received